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Conclusions: We conclude that transfusion of blood products is
an integral part of stem cell transplantation. Role of growth factors
and lowering the threshold of transfusion in an attempt to decrease
the need of transfusion should be studied in a prospective fashion.
Decreased survival in patients receiving more transfusion could be
due to the nature and severity of underlying disease rather than an
independent risk factor for survival.
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VACCINATION AGAINST INFECTION AFTER HAEMOPOIETIC STEM CELL
TRANSPLANT: A SURVEY OF PRACTICE IN THE UK & IRELAND (BRITISH
SOCIETY OF BONE MARROW TRANSPLANTATION)
Gilleece, M.H.1, Towlson, K.2, Wilson, M.2, Littlewood, T.3, Cook, G.1,
Marks, D.I.4 1Leeds Teaching Hospitals Trust, Leeds, Yorkshire, United
Kingdom; 2BSBMT Data Registry, London, United Kingdom; 3Oxford
Radcliffe Hospital, Oxford, United Kingdom; 4Bristol Royal Hospital for
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International guidelines recommend revaccination of haemopoietic
stem cell transplant (HSCT) recipients. We surveyed practice in
HSCT centres in the UK & Ireland. The response rate was 29/52
(56%): 9 did autologous (AUTO) transplants only & 20 performed
allografts/autografts in adults &/or children (AUTO/ALLO). Re-
sponders represented 58% of recorded transplants (2003-2005).
Vaccination post-autologous HSCT was intended by 4/9 AUTO
centres and 12/20 AUTO/ALLO centres. Vaccinations post-au-
tograft were given by centres as follows: Combined/selective Diph-
theria, Tetanus & Pertussis (DTP) (38%), Haemophilus B (HiB)
(45%) , Meningococcus C (MC) (34%), Poliomyelitis (Polio) (31%,
Salk), Hepatitis A (HA) (3%), Inﬂuenza A (Flu A) (45%) and Strep-
tococcus pneumoniae (SP) (45%). Selected patients were routinely
vaccinated against Measles / Mumps / Rubella (MMR) (28% centres)
and Hepatitis B (HB) (10%). Antibody titres or CD4 cell counts
guided timing of post-autologous HSCT vaccination in 4 & 1 centre
respectively.
Vaccinations post-allograft were planned by centres as follows:
DTP (100%), HiB (90%), MC (80%), Polio (95%, Salk), Flu A
(100%) and SP (95%). Selected patients were routinely vaccinated
against HB (25%) and HA (10%). CD4 cell counts guided timing of
post-allograft vaccination in 2 centres.
Live vaccines were avoided by 4 ALLO/AUTO centres: MMR was
given at 18-30 months post allograft in the rest provided there was no
active Graft versus Host Disease or ongoing Immunosuppressive
medication (I/S) . Bacillus Calmette Guerin was considered by 1
centre for high risk patients without GVHD or I/S.
Household contacts were advised to consider vaccination against Flu
A in 17% centres while Salk polio vaccine was advised by 10% centres.
Penicillin V prophylaxis against SP was recommended by 6
centres post Autograft for 6-12 months or life if Total Body
Irradiation had been given. Lifelong penicillin was advocated for
all allografted patients by 9 centres and in selected patients by 3
centres. Episodes of severe Pneumococccal sepsis was reported by
24% centres independent of prior vaccination or penicillin.
Reasons for large variation, particularly among autologous HSCT
recipients, may include lack of Grade A evidence, perceived poor
efﬁcacy and patient non-compliance. Systematic multicentre prospec-
tive evaluation of immune-reconstitution and incidence of speciﬁc
infections may clarify the value of post SCT vaccination in prevention
of life threatening infection.
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PROPHYLACTIC RED BLOOD CELL EXCHANGE FOR PREVENTION OF SE-
VERE HEMOLYSIS AFTER MINOR ABO-INCOMPATIBLE STEM CELL TRANS-
PLANTATION FOLLOWING REDUCED-INTENSITY CONDITIONING
Worel, N.1, Mitterbauer, M.2, Leitner, G.1, Rabitsch, W.2,
Greinix, H.2, Kalhs, P.2, Hoecker, P.1 1Dpt. f. Transfusion Medicine,
University Hospital, Vienna, Austria; 2Dpt. f. Bone Marrow Transplan-
tation, University Hospital, Vienna, Austria.
Background: In about 20% of allogeneic stem cell transplantation
(SCT) minor ABO incompatibility does exist. This is accompanied
with the risk of severe hemolysis especially during hematopoietic
regeneration. The risk of hemolysis increases if peripheral blood stem
cells are used instead of bone marrow (BM) and a graft-versus-host
disease (GvHD) prophylaxis without methotrexate (MTX). As we
have observed lethal hemolyses in patients undergoing minor ABO
mismatched SCT following reduced intensity conditioning (RIC) we
decided to perform prophylactic red blood cell exchange (RBCX) in
all consecutive patients undergoing RIC prior to SCT with a minor
ABO incompatible donor.
Materials and Methods: From April 1999 to March 2006, 112
consecutive patients underwent SCT with a sibling (n55) or unre-
lated donor graft (n57) after RIC. GvHD prophylaxis consisted of
CyA and mycophenolate mofetil (MMF). Fifty-four patients had an
ABO-identical donor, 33 received an ABO-minor/bidirectional and
25 an ABO-major incompatible graft, respectively. RBCX was per-
formed between day -5 and -1, removing 1 time patients RBCmass to
reduce his remaining RBCs to about 40%. Packed RBCS of group 0
were used as exchange ﬂuid.
Results: So far, 20 patients underwent prophylactic RBCX before
SCT. The procedure was tolerated well in 16 (80%) patients, 2
developed citrate toxicity and 2 nausea and hypotension during treat-
ment leading to discontinuation of RBCX in the latter patients.
Whereas 18 patients did not experience any signs of hemolysis after
minor ABO incompatible SCT, 2 showed a marked increase in lactic
dehydrogenase and serum bilirubin levels without a drop of hemato-
crit levels below 28% during hematologic recovery. Six of 20 patients
with prophylactic RBCX died between 4.3 and 29.2 months after
SCT of GvHD and infection (n3), invasive aspergillosis (n1) and
relapse of hematologic disease (n2). One patient rejected his graft
within 1 month. The other 13 (64%) patients are in continuous
complete remission a median of 13.9 months (1.2 to 36) after SCT.
Conclusion: RBCX is a save and well tolerated procedure to pre-
vent severe hemolysis by elimination of the majority of incompatible
recipient RBCs as demonstrated by our data. Whether a more inten-
sive immunosuppression can overcome the risk of hemolysis without
affecting the establishment of donor chimerism remains unclear. Nev-
ertheless, close monitoring of patients at risk between days 5 and 15
after SCT is recommended.
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CANCER PATIENTS
Kennedy, L.D.1, Gatesman, M.L.2, High, K.3, Karchmer, T.B.3 1Wake
Forest University Baptist Medical Center, Winston Salem, NC; 2Uni-
versity of Virginia Medical Center, Charlottesville, VA; 3Wake Forest
University School of Medicine, Winston Salem, NC.
Two recently published trials and a meta-analysis reported signiﬁ-
cantly reduced febrile episodes and mortality, respectively, with the
use of FQ prophylaxis in neutropenic cancer patients. Although this
data supports the use of antibiotic prophylaxis (AP), AP does not come
without risks. A concern exists for breakthrough infections withmulti-
drug resistant (MDR) organisms and colonization with resistant bac-
teria. Our institution initiated the use of AP to prevent febrile neu-
tropenia (FN) in high risk cancer patients after the reports above, and
assessed the efﬁcacy of AP in our patients and the incidence of MDR
infection and colonization in neutropenic cancer patients prior to and
after the implementation of AP.
Patients at high risk for FN (hematopoietic stem cell transplant,
leukemia patients undergoing induction or consolidation chemother-
apy, patients with a history of previous FN or undergoing a chemo-
therapy regimen with an expected duration of neutropenia 10 days)
were given AP (moxiﬂoxacin 400 mg daily) initiated the day after
chemotherapy and continued until neutropenia resolved or break-
through fever requiring broad spectrum antibiotics occurred.
Preliminary analysis of 81 patients showed that 38 patients (47%)
developed FN with a mean time to febrile episode of 10.9 days.
Eighteen patients were readmitted for FN, in 19 patients FN oc-
curred during the same hospitalization, and one patient was treated as
an outpatient with IV antibiotics. Seventeen (21%) patients had pos-
itive cultures: blood (6), urine (9), sputum (2). The rate of overall
microbiologically documented infection (21%) is similar, but the rate
of bacteremia (7%) lower than those reported in a similar risk patient
group using levoﬂoxacin AP (18%) (NEJM, 2005;335:977). Evalua-
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tion of surveillance cultures found only one patient developed colo-
nization with VRE after AP. Two patients had C. difﬁcile infection and
one patient C. glabrata in the urine during their AP. Data collection
remains ongoing and a comparison to historical infection data will be
presented.
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EFFECTS OF WARMING METHODS ON TEMPERATURE, CARDIAC FUNC-
TION AND IMMUNOLOGIC FUNCTION IN PLATELETPHERESIS DONORS
Kim, H.-J.1, Park, C.-W.2, Kim, N.-C2 1Catholic Institute of Cell
Therapy, Catholic University of Korea, Seoul, Korea; 2Department of
Hematology, Catholic University, Seoul, Korea; 3Nursing Collge, Cath-
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BACKGROUND
Hypothermia, which is a common side effect of apheresis, has
negative effects on the donor’s and patient’s body functions.
The aim of this study was to examine the effects of warming
methods on plateletpheresis donors’ temperature, cardiac and im-
munologic function.
STUDY DESIGN AND METHODS
50 plateletpheresis donors were randomly assigned to control
group(n25) or warming group(n25) with an air warmer and a
blood warmer during plateletpheresis. The effects of the treatment
were examined by comparing body temperature, heart rate, blood
pressure, Holter EKG pattern, serum Interleukin-1	(IL-1	), Inter-
leukin-2(IL-2), tumor necrosis factor- (TNF-) concentration,
white blood count, white blood fraction, platelet count by point of
time between the two groups.
RESULTS
Tympanic temperature decreased less in the treatment group than
in the control group. Systolic blood pressure decreased in both
groups, but the difference was not signiﬁcant. However, the decrease
of diastolic blood pressure was signiﬁcantly less in the treatment group
than in the control group. As for cardiac function, the frequency of
abnormal pulsation was generally lower in the treatment group, but
the difference was not signiﬁcant. IL-1	was not signiﬁcantly different
between the two groups. IL-2 and TNF- decreased signiﬁcantly
after plateletpheresis in the control group.
CONCLUSION
To reduce the risk of serious side effects, more careful monitor-
ing and intervention for change of cardiac & immunologic func-
tion is required in apheresis.
And warming methods can maintain the balance of tympanic
temperature, IL-2 and TNF-, warming methods is considered
more useful in patients of therapeutic apheresis.
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SAMPLE SIZE REQUIREMENTS FOR STUDIES IN WHICH TIME-TO-NEU-
TROPHIL-ENGRAFTMENT IS THE PRIMARY STATISTICAL ENDPOINT
Klumpp, T.P.1, Emmons, R.V.1, Martin, M.E.1, Gajewski, J.1,
Wirk, B.1, Mangan, K.F.1 1Fox Chase Temple University BMT Pro-
gram, Philadelphia, PA.
When planning clinical trials in which time-to-neutrophil-engraft-
ment is the primary statistical endpoint, it is critical to utilize an
appropriate sample size. Insufﬁcient sample size can result in a failure
to identify interventions that could have a meaningful effect on neu-
trophil recovery, whereas overly large sample size can lead to excessive
study cost and duration. To our knowledge, all currently available
software packages for calculating sample size base their estimates on
theoretical mathematical distributions rather than on the uniquely
distributed time-to-event proﬁles that characterize actual neutrophil
recovery following BMT. In order to address these issues, we have
developed a SAS-based clinical trials simulator in which the time-to-
engraftment probabilities are based directly on observed time-to-
engraftment distributions in actual cohorts of patients. By conducting
thousands of simulated trials, the power and sample size requirements
for detecting speciﬁed differences in engraftment time at a statistically
signiﬁcant level versus any desired reference population of patients
can be accurately estimated. Our initial series of simulations were
based on the time-to-engraftment distribution observed in a series of
actual patients undergoing melphalan-conditioned, ﬁlgrastim-sup-
ported autologous peripheral blood stem cell transplantation for mul-
tiple myeloma, and involved approximately 1.4 million simulated
patients enrolled on approximately 30,000 simulated randomized tri-
als. In the above-mentioned patient population, in which the neutro-
phil engraftment times are very tightly clustered around the mean, the
model estimated that only 37 patients would need to be randomized
to yield an 80% probability of detecting a 1-day difference in the
median neutrophil engraftment time at the p 0.05 signiﬁcance level,
and that only 48 patients would need to be randomized to yield a 90%
probability. Subsequent simulations will illustrate that sample size
requirements will be higher in patient populations in which the dis-
persion in neutrophil engraftment times is wider.
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IMPACT OF POSACONAZOLE (POS) VS FLUCONAZOLE (FLU) ON CY-
CLOSPORINE (CSA) AND TACROLIMUS (TAC) DOSING IN HEMATOPOI-
ETIC STEM CELL TRANSPLANT (HSCT) RECIPIENTS WITH GRAFT-VS-
HOST DISEASE (GVHD)
Langston, A.1, Lipton, J.H.2, Brundage, T.3, Patino, H.3,
Ullmann, A.J.4 1Emory University, Atlanta, GA; 2Princess Margaret
Hospital, Toronto, ON, Canada; 3Schering-Plough Research Institute
(currently Afﬁliated with Stiefel Research Institute, Parsippany, NJ),
Kenilworth, NJ; 4Johannes Gutenberg University, Mainz, Germany.
Background: HSCT recipients often receive the immunosup-
pressants CsA or TAC for GVHD concomitantly with an azole for
prevention of invasive fungal infection (IFI). As CsA and TAC are
metabolized by the cytochrome P450 enzyme, CYP3A4, and azoles
are CYP3A4 inhibitors, potential drug interactions are a concern.
CsA and TAC dose changes were analyzed in a trial of POS vs
FLU as IFI prophylaxis in HSCT recipients with GVHD.
Methods: 600 patients were randomized to receive POS (200 mg
po t.i.d., n301) or FLU (400 mg po q.d., n299) for up to 16 weeks.
A sample of subjects randomized at 3 major enrolling centers was
selected for examination of CsA and TAC dose adjustments at initi-
ation of prophylaxis and after 2 weeks of treatment, because CsA and
TAC levels typically decrease early during coadministration with
azoles.
Results: In the total study, 206 POS and 213 FLU patients
received CsA, while 47 POS and 50 FLU patients received TAC.
Therapeutic drug monitoring records were reviewed for 49 sub-
jects. CsA plasma levels were determined in 19 POS and 19 FLU
patients, and TAC plasma levels were determined in 7 POS and 5
FLU patients. Changes in CsA levels-to-dose ratio (C/D) were
comparable in both groups by week 2, increasing by 17% in POS
patients and 14% in FLU patients (table). Despite dosing adjust-
ments in both groups, CsA plasma levels decreased to a greater
extent in the FLU group. By week 2, TAC C/D and plasma levels
increased in the POS group but decreased in the FLU group.
Conclusion: These data suggest that POS and FLU have a similar
impact on CsA levels as shown by C/D ratio changes. CsA dose
reductions of approximately 30% to 45% upon initiation of prophy-
laxis are recommended in order to maintain effective drug levels
within the therapeutic range. Numbers of observations for TAC in
both groups were too low to draw any conclusions. Monitoring of
CsA or TAC levels during coadministration with an azole is recom-
mended.
POS FLU
Baseline Week 2 Change Baseline Week 2 Change
CsA n  19 n  19 n  19 n  19
Mean C/D 0.93 1.09 17% 1.25 1.43 14%
Mean plasma levels*
(ng/mL) 351.0 314.2 -10% 386.5 294.6 -24%
Mean dosing (mg/d) 570.9 307.8 -46% 365.8 263.2 -28%
TAC n  7 n  6 n  5 n  4
Mean C/D 3.43 4.39 28% 7.68 6.51 -15%
Mean plasma levels*
(ng/mL) 10.6 12.2 15% 14.9 13.8 -7%
Mean dosing (mg/d) 15.3 4.0 -74% 2.9 3.3 14%
*Highest value within interval
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